ROLAPITANT HYDROCHLORIDE
|
- ₹0
- Product name: ROLAPITANT HYDROCHLORIDE
- CAS: 914462-92-3
- MF: C25H29ClF6N2O3
- MW: 554.96
- EINECS:682-730-5
- MDL Number:MFCD23105917
- Synonyms:Rolapitant Hydrochloride Hydrate;RolapitantMonohydrochloride;ROLAPITANT HYDROCHLORIDE;1,7-Diazaspiro[4.5]decan-2-one, 8-[[(1R)-1-[3,5-bis(trifluoroMethyl)phenyl]ethoxy]Methyl]-8-phenyl-, Monohydrochloride, Monohydrate, (5S,8S)-;(5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one,hydrate,hydrochloride;Rolapitant Hydrochloride Monohydrate;Rolapitant HCl hydrate;1,7-Diazaspiro[4.5]decan-2-one, 8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-, hydrochloride, hydrate (1:1:1), (5S,8S)-
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Melting point :>149oC (dec.)
storage temp. :Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
color :White
storage temp. :Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
color :White
Safety Information
| Symbol(GHS): |
 
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||||||||||
| Hazard statements: |
|
||||||||||||||||||||||
| Precautionary statements: |
|
Description
Rolapitant hydrochloride hydrate, originally discovered by Schering-Plough and later developed by TESARO, Inc., was approved by the FDA in September 2015 for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in combination with other antiemetic agents. Rolapitant is a highly selective NK-1 receptor antagonist, exhibiting >1000- fold selectivity for NK-1 over human NK-2 and NK-3 receptors in vitro. In contrast to other NK-1 inhibitors that play an essential role in delayed CINV therapy, rolapitant shows no inhibition of CYP3A4, eliminating the need for concern when coadministering with CYP34A substrates. Additionally, rolapitant is an orally active agent with a relatively long half-life (180 h), providing potential opportunities for single- and prechemotherapy-based treatments. In three large clinical trials involving patients receiving moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC), subjects using rolapitant as a cotherapy with granisetron and dexamethasone showed a significant improvement in complete response compared to those receiving treatments of granisetron and dexamethasone.More related product prices
Rolapitant
